Publications

These are publications from work undertaken by Frontier Science (Scotland).

M Procter;  T M Suter; E. de Azambuja; U Dafni; V Van Dooren; S Muehlbauer; M Angel Climent; E Rechberger; W Tsang-Wu Liu; M Toi; R C Coombes; D Dodwell; O Pagani; J Madrid; M Hall; S Chen; C Focan; M Muscholl; D J van Veldhuisen; M Piccart-Gebhart;  2010

Longer term assessment of trastuzumab for 1 year after adjuvant chemotherapy

Journal of Clinical Oncology,  Volume 28, Issue 21, Pages 3422-3428, doi: 10.1200/JCO.2009.26.0463


M Dowsett;  M Procter; M McCaskill-Stevens; M E de Azambuja; U Dafni;  2009

Disease free survival according to the degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year trastuzumab: the HERA trial

Journal of Clinical Oncology,  Volume 27, Issue 18, Pages 2962-2969, doi: 10.1200/JCO.2008.19.7939


M Untch;  RD Gelber; C Jackisch; M Procter; J Baselga; R Bell; D Cameron; M Bari; I Smith; B Leyland-Jones; E. de Azambuja; R Khasanov; F Feng-yi; C Constantin; J Mayordomo; C H Su; S Y Yu; E Senkus-Konefka; A Lluch; P Wermuth; C Price;  2008

Estimating the Magnitude of Trastuzumab effects within patient subgroups in the HERA trial

Annals of Oncology,  Volume 19, Issue 6, Pages 1090-1096, doi: 10.1093/annonc/mdn005


T M Suter;  M Procter; D J van Veldhuisen; M Muscholl; J Bergh; C Carlomagno; T Perren; R Passalacqua; C Bighin; J G M Klijn; F Ageev; E Hitre; J Groetz; H Iwata; M Knap; M Gnant; S Muehlbauer; A Spence; RD Gelber; M Piccart-Gebhart;  2007

Trastuzumab-Associated cardiac adverse effects in the Herceptin Adjuvant trial

Journal of Clinical Oncology,  Volume 25, Pages 3859-3865, doi:10.1200/JCO.2006.09.1611


I Smith;  M Procter; RD Gelber; S Guillaume; A Feyereislova; M Dowsett; A Goldhirsch; M Untch; G Mariani; J Baselga; M Kaufmann; D Cameron; R Bell; J Bergh; A Wardley; N Harbeck; R I Lopez-Sanchez; P Mallmann; K Gelmon; N Wilcken; E Wist; P Sánchez Rovira; R Coleman;  2007

2 Year follow up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial

The Lancet,  Volume 369, Issue 9555, Pages 29-36, doi:10.1016/S0140-6736(07)60028-2


E. de Azambuja;  M Procter; D J van Veldhuisen; D Agbor-Tarh; O Metzger-Filho; J Steinseifer; M Untch; I Smith; L Gianni; J Baselga; C Jackisch; D Cameron; R Bell; B Leyland-Jones; M Dowsett; RD Gelber; M Piccart-Gebhart; T M Suter;  2014

Trastuzumab-associated cardiac events at 8 years of median follow up in the herceptin adjuvant trial (BIG 1-01)

Journal of Clinical Oncology,  Volume 32, Issue 20, Pages 2159-2165, doi:10.1200/JCO.2013.53.9288


A Sonnenblick;  D Agbor-Tarh; I Bradbury; S Di Cosimo; J A Zujewski; H A Azim Jr; J Judith; M Andersson; T Cufer; S Simon; P Salman; M Toi; L Harris; J Gralow; A Moreno-Aspitia; M. Piccart; E. de Azambuja; K Macoon;  2016

The Impact of Diabetes and Metformin Usage on the Outcome of HER2 Positive Primary Breast Cancer Patients. Analysis from the ALTTO Phase III Randomized Trial

European Journal of Cancer,  Volume 57, Issue 2, Pages S155-S167, doi: 10.1200/JCO.2016.69.7722


R Jover;  M Bretthauer; E Dekker; Ø Holme; M F Kaminski; M Loberg; A G Zauber; M A Hernan; I Lansdorp-Vogelaar; A Sunde; E McFadden; A Castells; E Quintero; M Pellise; C Senore; M Kalager; M Dinis-Ribeiro; L Emilsson; D Ransohoff; G Hoff; H Adami;  2016

Rationale and Design of the European Polyp Surveillance (EPoS) Trials

Endoscopy,  Volume 48, Issue 6, Pages 571-578, doi:10.1055/s-0042-104116


M Bretthauer;  M F Kaminski; M Loberg; A G Zauber; J Regula; E J Kuipers; M A Hernan; E McFadden; A Sunde; M Kalager; E Dekker; I Lansdorp-Vogelaar; K Garborg; M Rupinski; M Spaander; M Bugajski; O Hoie; T Stefansson; G Hoff; H Adami; NordICC Study Group;  2016

Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial

JAMA Internal Medicine,  Volume 176, Issue 7, Pages 894-902, doi:10.1001/jamainternmed.2016.0960


P L Bedard;  S K Singhal; M Ignatiadis; I Bradbury; B Haibe-Kains; C Desmedt; S Loi; D B Evans; S Michiels; J M Dixon; W R Miller; M. Piccart; C Sotiriou;  2011

Low Residual Proliferation after Short-Term Letrozole Therapy is an Early Predictive Marker of Response in High Proliferative ER-Positive Breast Cancer

Endocrine Related Cancer,  Volume 18, Issue 6, Pages 721-730, doi:10.1530/ERC-11-0180